Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,165.08
(
0.80%
)
US TECH 100
26,538.40
(
1.85%
)
Dow Jones
49,230.71
(
-0.16%
)
Brent Oil
100.66
(
0.00%
)
Bitcoin
78,072.11
(
0.58%
)
News Focus
News Focus
Post# of 257443
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122886
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: rkrw post# 124074

Thursday, 07/28/2011 1:32:04 PM

Thursday, July 28, 2011 1:32:04 PM

Post# of 257443

If HCV were the primary driver of Promacta sales I would look for them to raise their pricing.

I don’t think HCV will be a major portion of Promacta sales, so it may not be advisable to raise the price to coincide with the shortened average duration of interferon usage. It’s a Catch-22.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today